SEC Info - Seneca Capital Advisors LLC - ‘5’ for 6/30/03 re: Sevion Therapeutics, Inc.

FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0362
Estimated average burden
hours per response:			1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

1. Name and Address of Reporting Person^*

SENECA CAPITAL ADVISORS LLC

(Last)

(First)

(Middle)

527 MADISON AVE

11TH FL

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SENESCO TECHNOLOGIES INC [ SNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
6/30/03

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, $0.01 par value	9/30/02		S4	600	D	$1.92	1,606,543	I	See Footnotes 1,2
Common stock, $0.01 par value	10/2/02		S4	5,000	D	$1.91	1,601,543	I	See Footnotes 1,2
Common stock, $0.01 par value	10/7/02		S4	10,000	D	$1.87	1,591,543	I	See Footnotes 1,2
Common stock, $0.01 par value	11/4/02		S4	1,000	D	$2.02	1,590,543	I	See Footnotes 1,2
Common stock, $0.01 par value	11/5/02		S4	28,500	D	$2.59	1,562,043	I	See Footnotes 1,2
Common stock, $0.01 par value	4/4/03		S4	50,000	D	$1.91	1,512,043	I	See Footnotes 1,2
Common stock, $0.01 par value	4/11/03		S4	9,200	D	$2	1,502,843	I	See Footnotes 1,2
Common stock, $0.01 par value	4/14/03		S4	15,000	D	$2	1,487,843	I	See Footnotes 1,2
Common stock, $0.01 par value	4/15/03		S4	8,000	D	$2.05	1,479,843	I	See Footnotes 1,2
Common stock, $0.01 par value	4/21/03		S4	24,500	D	$2.15	1,455,343	I	See Footnotes 1,2
Common stock, $0.01 par value	4/22/03		S4	10,000	D	$1.99	1,445,343	I	See Footnotes 1,2
Common stock, $0.01 par value	5/6/03		S4	600	D	$2.03	1,444,743	I	See Footnotes 1,2
Common stock, $0.01 par value	6/23/03		S4	14,200	D	$2.4	1,430,543	I	See Footnotes 1,2
Common stock, $0.01 par value	6/24/03		S4	10,800	D	$2.05	1,419,743	I	See Footnotes ⁽¹⁾ ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

(1) Shares are held by Seneca Capital, L.P. of which Seneca Capital Advisors, LLC is the General Partner. Douglas A. Hirsch is the Managing Member of Seneca Capital Advisors, LLC. Each of Seneca Capital Advisors, LLC and Douglas A. Hirsch disclaim beneficial ownership of these securities except to the extent of its or his pecuniary interest therein and nothing in this report shall be deemed to be an admission by any of them that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The business address for Seneca Capital, L.P., Seneca Capital Advisors, LLC and Douglas A. Hirsch is 527 Madison Avenue, 11th Floor, New York, NY 10022.

(2) Column 5 includes warrants held by Seneca Capital, L.P. to purchase 375,000 shares of common stock at an exercise price of $2.00 per share and to purchase an additional 375,000 shares of common stock at an exercise price of $3.25 per share.

	Douglas A. Hirsch, as Managing Member of Seneca Capital Advisors, LLC, the General Partner of Seneca Capital, L.P.	9/30/03
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Codes:
S	Open market or private sale of non-derivative or derivative security.
4	A Form 4 Transaction.

Seneca Capital Advisors LLC – ‘5’ for 6/30/03 re: Sevion Therapeutics, Inc.

On: Tuesday, 9/30/03, at 9:23pm ET · For: 6/30/03 · As: 10% Owner · Accession #: 1058217-3-200 · File #: 1-31326

Annual Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 5 — SEA’34
Filing Table of Contents

This ‘5’ Document is an XML Data File that may be rendered in various formats:

Seneca Capital Advisors LLC – ‘5’ for 6/30/03 re: Sevion Therapeutics, Inc.

On: Tuesday, 9/30/03, at 9:23pm ET · For: 6/30/03 · As: 10% Owner · Accession #: 1058217-3-200 · File #: 1-31326

Annual Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 5 — SEA’34Filing Table of Contents

This ‘5’ Document is an XML Data File that may be rendered in various formats:

Annual Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 5 — SEA’34
Filing Table of Contents